2487 — Cutia Therapeutics Cashflow Statement
0.000.00%
- HK$1.93bn
- HK$1.34bn
- CNY279.62m
Annual cashflow statement for Cutia Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -320 | -556 | -1,964 | -434 |
Depreciation | ||||
Amortisation | ||||
Non-Cash Items | 184 | 330 | 1,545 | 48.1 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -34 | -29.1 | -5.42 | -102 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Prepaid Expenses | ||||
Change in Payable / Accrued Expenses | ||||
Cash from Operating Activities | -160 | -236 | -381 | -443 |
Capital Expenditures | -25.9 | -135 | -55.9 | -25.7 |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Other Investing Cash Flow Items | -385 | 597 | -148 | 342 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | -411 | 462 | -204 | 316 |
Financing Cash Flow Items | -0.148 | -3.37 | -10 | -5.98 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 481 | -10.2 | 588 | 37.8 |
Foreign Exchange Effects | ||||
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -97 | 263 | 7.25 | -87.5 |